An Open-Label Phase 2 Study to Evaluate PT2977 for the Treatment of Von Hippel Lindau Disease-Associated Renal Cell Carcinoma

Status: Active, no longer recruiting

Phase of Trial: Phase II

Latest Information Update: 15 Jul 2024

Price : $35 ^*

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Belzutifan (Primary)
Indications Haemangioblastoma; Neuroendocrine tumours; Pancreatic cancer; Renal cell carcinoma; Von Hippel-Lindau disease
Focus Registrational; Therapeutic Use
Acronyms LITESPARK-004
Sponsors Merck Sharp & Dohme Corp.; Peloton Therapeutics

10 Apr 2024 Results ( As of April 3, 2023, n=36) assessing safety and efficacy of Belzutifan presented at the 115th Annual Meeting of the American Association for Cancer Research
21 Oct 2023 According to a Merck & Co Media Release, additional applications are currently under regulatory agency review worldwide based on LITESPARK-004.
06 Jun 2023 Results for the subgroup of patients with CNS HBs presented at the 59th Annual Meeting of the American Society of Clinical Oncology

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com